Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML
© 2024 by The American Society of Hematology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)..
ABSTRACT: Molecular failure in NPM1-mutated acute myeloid leukemia (AML) inevitably progresses to frank relapse if untreated. Recently published small case series show that venetoclax combined with low-dose cytarabine or azacitidine can reduce or eliminate measurable residual disease (MRD). Here, we report on an international multicenter cohort of 79 patients treated for molecular failure with venetoclax combinations and report an overall molecular response (≥1-log reduction in MRD) in 66 patients (84%) and MRD negativity in 56 (71%). Eighteen of 79 patients (23%) required hospitalization, and no deaths were reported during treatment. Forty-one patients were bridged to allogeneic transplant with no further therapy, and 25 of 41 were MRD negative assessed by reverse transcription quantitative polymerase chain reaction before transplant. Overall survival (OS) for the whole cohort at 2 years was 67%, event-free survival (EFS) was 45%, and in responding patients, there was no difference in survival in those who received a transplant using time-dependent analysis. Presence of FLT3-ITD mutation was associated with a lower response rate (64 vs 91%; P < .01), worse OS (hazard ratio [HR], 2.50; 95% confidence interval [CI], 1.06-5.86; P = .036), and EFS (HR, 1.87; 95% CI, 1.06-3.28; P = .03). Eighteen of 35 patients who did not undergo transplant became MRD negative and stopped treatment after a median of 10 months, with 2-year molecular relapse free survival of 62% from the end of treatment. Venetoclax-based low intensive chemotherapy is a potentially effective treatment for molecular relapse in NPM1-mutated AML, either as a bridge to transplant or as definitive therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Blood advances - 8(2024), 2 vom: 23. Jan., Seite 343-352 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 31.01.2024 Date Revised 08.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1182/bloodadvances.2023011106 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36530509X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36530509X | ||
| 003 | DE-627 | ||
| 005 | 20240209232002.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/bloodadvances.2023011106 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1285.xml |
| 035 | |a (DE-627)NLM36530509X | ||
| 035 | |a (NLM)38039513 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jimenez-Chillon, Carlos |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.01.2024 | ||
| 500 | |a Date Revised 08.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 by The American Society of Hematology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). | ||
| 520 | |a ABSTRACT: Molecular failure in NPM1-mutated acute myeloid leukemia (AML) inevitably progresses to frank relapse if untreated. Recently published small case series show that venetoclax combined with low-dose cytarabine or azacitidine can reduce or eliminate measurable residual disease (MRD). Here, we report on an international multicenter cohort of 79 patients treated for molecular failure with venetoclax combinations and report an overall molecular response (≥1-log reduction in MRD) in 66 patients (84%) and MRD negativity in 56 (71%). Eighteen of 79 patients (23%) required hospitalization, and no deaths were reported during treatment. Forty-one patients were bridged to allogeneic transplant with no further therapy, and 25 of 41 were MRD negative assessed by reverse transcription quantitative polymerase chain reaction before transplant. Overall survival (OS) for the whole cohort at 2 years was 67%, event-free survival (EFS) was 45%, and in responding patients, there was no difference in survival in those who received a transplant using time-dependent analysis. Presence of FLT3-ITD mutation was associated with a lower response rate (64 vs 91%; P < .01), worse OS (hazard ratio [HR], 2.50; 95% confidence interval [CI], 1.06-5.86; P = .036), and EFS (HR, 1.87; 95% CI, 1.06-3.28; P = .03). Eighteen of 35 patients who did not undergo transplant became MRD negative and stopped treatment after a median of 10 months, with 2-year molecular relapse free survival of 62% from the end of treatment. Venetoclax-based low intensive chemotherapy is a potentially effective treatment for molecular relapse in NPM1-mutated AML, either as a bridge to transplant or as definitive therapy | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Bridged Bicyclo Compounds, Heterocyclic |2 NLM | |
| 650 | 7 | |a NPM1 protein, human |2 NLM | |
| 650 | 7 | |a Nuclear Proteins |2 NLM | |
| 650 | 7 | |a Nucleophosmin |2 NLM | |
| 650 | 7 | |a 117896-08-9 |2 NLM | |
| 650 | 7 | |a Sulfonamides |2 NLM | |
| 650 | 7 | |a venetoclax |2 NLM | |
| 650 | 7 | |a N54AIC43PW |2 NLM | |
| 700 | 1 | |a Othman, Jad |e verfasserin |4 aut | |
| 700 | 1 | |a Taussig, David |e verfasserin |4 aut | |
| 700 | 1 | |a Jimenez-Vicente, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Martinez-Roca, Alexandra |e verfasserin |4 aut | |
| 700 | 1 | |a Tiong, Ing Soo |e verfasserin |4 aut | |
| 700 | 1 | |a Jain, Manish |e verfasserin |4 aut | |
| 700 | 1 | |a Aries, James |e verfasserin |4 aut | |
| 700 | 1 | |a Cakmak, Seda |e verfasserin |4 aut | |
| 700 | 1 | |a Knapper, Steven |e verfasserin |4 aut | |
| 700 | 1 | |a Kristensen, Daniel Tuyet |e verfasserin |4 aut | |
| 700 | 1 | |a Murthy, Vidhya |e verfasserin |4 aut | |
| 700 | 1 | |a Galani, Joy Zacharoula |e verfasserin |4 aut | |
| 700 | 1 | |a Kallmeyer, Charlotte |e verfasserin |4 aut | |
| 700 | 1 | |a Ngu, Loretta |e verfasserin |4 aut | |
| 700 | 1 | |a Veale, David |e verfasserin |4 aut | |
| 700 | 1 | |a Bolam, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Orfali, Nina |e verfasserin |4 aut | |
| 700 | 1 | |a Parker, Anne |e verfasserin |4 aut | |
| 700 | 1 | |a Manson, Cara |e verfasserin |4 aut | |
| 700 | 1 | |a Parker, Jane |e verfasserin |4 aut | |
| 700 | 1 | |a Erblich, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Richardson, Deborah |e verfasserin |4 aut | |
| 700 | 1 | |a Mokretar, Katya |e verfasserin |4 aut | |
| 700 | 1 | |a Potter, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Overgaard, Ulrik Malthe |e verfasserin |4 aut | |
| 700 | 1 | |a Roug, Anne Stidsholt |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Andrew H |e verfasserin |4 aut | |
| 700 | 1 | |a Esteve, Jordi |e verfasserin |4 aut | |
| 700 | 1 | |a Jädersten, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Russell, Nigel |e verfasserin |4 aut | |
| 700 | 1 | |a Dillon, Richard |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood advances |d 2016 |g 8(2024), 2 vom: 23. Jan., Seite 343-352 |w (DE-627)NLM268683263 |x 2473-9537 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2024 |g number:2 |g day:23 |g month:01 |g pages:343-352 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1182/bloodadvances.2023011106 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2024 |e 2 |b 23 |c 01 |h 343-352 | ||